S'abonner

Increased risk of colorectal adenomas with metabolic-associated fatty liver disease components - 07/03/24

Doi : 10.1016/j.clinre.2024.102302 
Dongsheng Ran a, ChunLing Xin b, Yingcai Ma c, 1, , Yanyan Lu c, 1,
a Graduate School of Qinghai University, Xining Qinghai 810000, China 
b Department of Paediatrics The Central Hospital of Xiaogan, Xiaogan HuBei 432000, China 
c Department of Gastroenterology, Qinghai Provincial People's Hospital, Xining Qinghai 810000, China 

Corresponding authors at: #2 Gonghe Road, Xining, Qinghai Province, P.R. China, 810000.#2 Gonghe RoadXiningQinghai Province810000P.R. China

Highlights

Utilizing the updated MAFLD nomenclature, we pioneered an increased risk of CRA with MAFLD components.
Our research further evaluated the accuracy of FLI in screening CRA.
Future efficient screening strategies may be derived from insights into MAFLD and FLI.

Le texte complet de cet article est disponible en PDF.

Abstract

Background

Metabolic (dysfunction)-associated fatty liver disease is the most common liver disease related to various metabolic disorders. Colorectal adenomas are related to metabolic dysregulation. Despite the proposed association between non-alcoholic fatty liver disease and colorectal adenomas, the influence of metabolic-associated fatty liver disease on colorectal adenomas has yet to be investigated. Our study investigates the relationship between metabolic-associated fatty liver disease and colorectal adenomas and evaluates the predictive value of fatty liver index for colorectal adenomas.

Methods

A retrospective cross-sectional study was conducted on 650 inpatients at Qinghai Provincial People's Hospital. All participants underwent colonoscopy, abdominal ultrasound or CT, relevant laboratory tests, and physical examinations to ascertain baseline characteristics and overall health status. Multivariate logistic regression analysis examined the relationship between metabolic-associated fatty liver disease and colorectal adenomas. Lastly, the ability to identify, accuracy, and clinical applicability of predicting colorectal adenomas through fatty liver index were assessed using receiver operating characteristic curve area under the curve, calibration curve, and decision curve analysis.

Result

In both the colorectal adenomas and control groups, the prevalence of metabolic-associated fatty liver disease was 62.1 % and 35.7 %, respectively. Multivariate analysis indicates that metabolic-associated fatty liver disease was independently correlated with an increased risk of colorectal adenomas (OR, 1.565; 95 % CI, 1.057–2.319; P < 0.05). Further analysis revealed that the risk of colorectal adenomas increased with an increasing quantity of metabolic components in metabolic-associated fatty liver disease (Ptrend < 0.001). The area under the curve of the fatty liver index predictive model was 0.838, with a 95 % CI of 0.807–0.869. The calibration curve indicated excellent agreement, and the decision curve analysis revealed a higher net benefit.

Conclusion

The risk of colorectal adenomas was associated with metabolic-associated fatty liver disease, and the risk of developing colorectal adenomas increased with the presence of more metabolic-associated fatty liver disease metabolic components. Furthermore, fatty liver index served as a predictive indicator for screening colorectal adenomas.

Le texte complet de cet article est disponible en PDF.

Keywords : Metabolic-associated fatty liver disease, Colorectal adenomas, Metabolic components, Fatty liver index, Validating prediction model


Plan


© 2024  Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 48 - N° 3

Article 102302- mars 2024 Retour au numéro
Article précédent Article précédent
  • Computed tomography-guided percutaneous cryoablation and microwave ablation in the treatment of perivascular hepatocellular carcinoma: A comparative study with propensity score matching
  • Bing Li, Zi Wang Ren, Chuan Zhang, Xiao Xuan Yu, Xiao Xue Xu, Yong Du, Han Feng Yang
| Article suivant Article suivant
  • Efficacy and safety of precutting endoscopic mucosal resection versus endoscopic submucosal dissection for non-ampullary superficial duodenal lesions
  • Dawei Chen, Sunya Fu, Jianwei Shen

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.